Stay Current at INTERPHEX - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Stay Current at INTERPHEX
An established show has several new programs that reflect the industry's current challenges.


Pharmaceutical Technology
Volume 34, Issue 4, pp. 14


Erik Greb
In addition to showcasing the latest innovations in pharmaceutical manufacturing equipment, INTERPHEX 2010 will help attendees stay current through various new presentations and discussions. Pharmaceutical Technology is partnering with INTERPHEX to present speakers from the US Food and Drug Administration, Rx–360, and PharmSource, a provider of business intelligence. Conference visitors will hear representatives of these groups discuss deficiencies in new drug applications, trends in supply-chain security, and the state of the outsourcing industry. Best of all, the speakers will take time to answer questions from the audience.

Although INTERPHEX is associated with small-molecule manufacturing, the conference is broadening its offerings for professionals involved in large-molecule production. BioPharm International, our sister publication, organized the keynote presentation this year about the effect of healthcare reform on the biopharmaceutical industry. MSNBC's Chris Matthews will moderate the discussion.

And each day, my colleagues and I will be conducting live interviews with various industry experts. We'll be giving you the scoop about quality-by-design implementation, packaging innovations, harmonization, and high-potency drugs. Our interviews will be videotaped and featured on our website after the conference.

INTERPHEX 2010 promises to keep attendees informed about the latest trends and innovations shaping the drug industry. I hope to see you there!

Check out PharmTech's preliminary program for its live video interviews at Interphex 2010

Erik Greb is an assistant editor of Pharmaceutical Technology.

Read Erik's blogs at http://blog.PharmTech.com/.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here